These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22379455)

  • 21. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
    Johnson KP
    Ther Clin Risk Manag; 2010 Apr; 6():153-72. PubMed ID: 20421914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.
    Stuart WH; Cohan S; Richert JR; Achiron A
    Neurology; 2004 Dec; 63(11 Suppl 5):S19-27. PubMed ID: 15596732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
    Candido K; Soufi H; Bandyopadhyay M; Dasgupta S
    Mini Rev Med Chem; 2016; 16(7):547-54. PubMed ID: 26156414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.
    Khan O; Zabad R; Caon C; Zvartau-Hind M; Tselis A; Lisak R
    CNS Drugs; 2002; 16(8):563-78. PubMed ID: 12096936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferons and natalizumab for multiple sclerosis.
    Clar C; Velasco Garrido M; Gericke C; Busse R
    GMS Health Technol Assess; 2008 Oct; 4():Doc09. PubMed ID: 21289915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract]   [Full Text] [Related]  

  • 36. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract]   [Full Text] [Related]  

  • 38. Ublituximab (Briumvi) for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2023 Mar; 65(1671):36-38. PubMed ID: 36877282
    [No Abstract]   [Full Text] [Related]  

  • 39. Natalizumab in the treatment of multiple sclerosis.
    Brown BA
    Ther Clin Risk Manag; 2009 Jun; 5(3):585-94. PubMed ID: 19707275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.
    Jankovic SM
    J Inflamm Res; 2010; 3():25-31. PubMed ID: 22096354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.